News

Two molecules, 5-hydroxyindoleacetic acid (5-HIAA) and insulin-like growth factor 1 (IGF-1), showed a potential to diagnose pulmonary hypertension  early in children with congenital heart disease based on their levels in blood and urine samples examined in a study. 5-HIAA is the main product of the breakdown of serotonin, a…

Healthcare costs were found to be more than eight times higher for people with pulmonary arterial hypertension (PAH) compared with patients without the disease in a real-world study — which contributed to the greater economic burden seen for those being treated for PAH. These costs were mainly driven by…

Sildenafil — a medication that relaxes blood vessels, thereby increasing blood flow — may possibly be used to treat neonatal pulmonary hypertension in babies born at high altitudes, where less oxygen is available for breathing. This is according to clinical observations by Alexandra Heath-Freudenthal, MD, a pediatric cardiologist, while…

High blood levels of resistin, a hormone produced by fat cells, may help identify pulmonary arterial hypertension (PAH) patients at higher risk of clinical worsening, a large U.S. study suggests. Resistin levels also could separate people with idiopathic, or unknown cause, PAH (iPAH) or…

The U.S. Food & Drug Administration (FDA) has tentatively approved Alembic Pharmaceuticals‘ generic formulation of injectable selexipag as a treatment for pulmonary arterial hypertension (PAH). As a generic drug, which contains the same chemical substance as an approved treatment, it’s equivalent to Uptravi (selexipag) for injection (1,800…

A natural substance isolated from a houseplant shows promise as a potential treatment to prevent and reverse pulmonary hypertension (PH), a study found. Treatment with FR900359 (FR) reversed the disease in a mouse model of PH, and relaxed pulmonary arteries of mice, pigs, and humans. FR activity was equivalent…

Reviva Pharmaceuticals has been granted a patent in Europe that covers using brilaroxazine, formerly RP5063, for pulmonary hypertension (PH). The patent covers patients with pulmonary arterial hypertension (PAH) and those who develop PH associated with chronic obstructive pulmonary disease (COPD), an inflammatory lung disorder, or sickle…

Anumana‘s artificial intelligence (AI) algorithm shows promise for the early detection of pulmonary hypertension (PH), a study suggested. The PH Early Detection Algorithm, which analyzes data collected from a routine electrocardiogram (ECG) heart test, was developed by scientists at Anumana, Janssen Research and Development, the Mayo Clinic,…

A global clinical trial evaluating a pulmonary artery denervation (PADN) device in people with pulmonary hypertension (PH) associated with left heart disease has launched in Europe, with the first two patients enrolled at a hospital in Portugal, Pulnovo Medical, the device’s developer, announced. These two adults have undergone…

An advisory committee of the European Medicines Agency (EMA) is recommending that Winrevair (sotatercept) be approved for the treatment of pulmonary arterial hypertension (PAH) in the Europe Union. Specifically, the Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending that Winrevair to be used in…

A new study identifies the presence of bacteria from the genus Eubacterium fissicatena, known for their pro-inflammatory properties, as a risk factor for pulmonary arterial hypertension (PAH). While the findings suggest “specific intestinal bacteria” are biomarkers for pulmonary PAH, and show “compelling evidence” that connects gut imbalance, or dysbiosis,…

Tempus AI and United Therapeutics are teaming up for a study to advance the use of artificial intelligence (AI) for detecting people at risk of having undiagnosed pulmonary hypertension. “We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into…